Poxel Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Poxel şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Geri Alım Getirisi

Toplam Hissedar Getirisi	n/a
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Mar 27

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

May 07

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 16

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

Nov 17

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: POXEL şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: POXEL şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Poxel Piyasaya Karşı Temettü Getirisi

POXEL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (POXEL)	n/a
Pazarın Alt %25'i (FR)	2.1%
Pazarın En İyi %25'i (FR)	5.5%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (POXEL) (3 yıla kadar)	0%

Önemli Temettü: POXEL şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, POXEL şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: POXEL şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: POXEL herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Poxel Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Poxel S.A. Provides Revenue Guidance for the Full Year 2024

Poxel S.A., Annual General Meeting, Nov 28, 2024

Full year 2023 earnings released

New major risk - Financial data availability

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

New major risk - Shareholder dilution

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

New major risk - Share price stability

First half 2023 earnings released

Poxel S.A. to Report Q2, 2023 Results on Sep 26, 2023

Consensus revenue estimates decrease by 43%

Poxel S.A., Annual General Meeting, Jun 21, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 32%

Poxel S.A. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Consensus forecasts updated

First half 2022 earnings released

Poxel S.A. Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone

Price target decreased to €11.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Poxel S.A. Announces Pxl065 and Pxl770 Granted Orphan Drug Designation from the U.S. Fda for X Linked Adrenoleukodystrophy

Poxel S.A., Annual General Meeting, Jun 21, 2022

Price target decreased to €13.43

Insufficient new directors

Poxel Announces PXL770 Wins FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

Insufficient new directors

Consensus revenue estimates fall by 28%

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Insufficient new directors

Poxel Announces PXL065 Granted FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

First half 2021 earnings released

POXEL SA Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Poxel S.A. Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases

Consensus forecasts updated

Poxel Presents Results of Two Clinical Studies on Its Direct Amp Kinase Activator, the Pxl770

Poxel SA and Sumitomo Dainippon Pharma Co., Ltd. Announces Approval of TWYMEEG for Treatment of Type 2 Diabetes in Japan

Poxel S.A. Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS)

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

Full year 2020 earnings released

New 90-day high: €7.62

Poxel S.A. Terminates Partnership Agreement with Metavant

Poxel S.A. to Report Q3, 2021 Results on Oct 20, 2021

Price target lowered to €15.83

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH

Poxel Provides Update on Metavant Partnership with Imeglimin

Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting 2020

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

New 90-day high: €7.19

New 90-day low: €6.00

Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

Poxel S.A. Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting

First half earnings released

New 90-day low - €6.13

New 90-day low - €6.38

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin